A carregar...
Advances in the management of HER2-positive early breast cancer
While trastuzumab is firmly established as the cornerstone of therapy for both early and advanced breast cancer expressing human epidermal growth factor receptor 2 (HER2), many patients either do not respond to trastuzumab treatment or progress following therapy. Improved understanding of breast can...
Na minha lista:
| Publicado no: | Crit Rev Oncol Hematol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5662944/ https://ncbi.nlm.nih.gov/pubmed/29042085 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.critrevonc.2017.10.001 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|